Navigation Links
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
Date:3/7/2013

in moderately to severely active CD and UC patients, who had failed at least one conventional or anti-TNFα therapy.

"With a targeted mechanism of action, vedolizumab has clinical promise as a potential treatment option for people with moderate to severely active CD and UC," said Paul Rutgeerts, M.D., Ph.D., F.R.C.P., professor of medicine, Catholic University of Leuven, Belgium. "While there is no known cure, there is a need for new CD and UC treatment options, in an effort to provide patients with additional choices for managing their disease, reducing symptoms and achieving remission."

About Crohn's disease and ulcerative colitis

Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD), which is marked by inflammation in the lining of the GI tract. CD can impact any part of the digestive tract, and common symptoms may include abdominal pain, diarrhea, rectal bleeding, weight loss, and/or fever. UC impacts the large intestine only, which includes the colon and the rectum. The most common symptoms of UC include abdominal discomfort and blood or pus in diarrhea. There is no known cause for CD or UC, although many researchers believe that the interaction of an outside agent, such as a virus or bacteria, with the body's immune system may trigger them. No cure exists for CD or UC; the aim of IBD treatments is to induce and maintain remission, or achieve extended periods of time when patients do not experience symptoms.

About vedolizumab

Vedolizumab was developed for the treatment of CD and UC, as a gut-selective, humanized monoclonal antibody that specifically antagonizes the alpha4beta7 (α4β7) integrin, which is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in CD and UC. α4β7 binds with a specific adhesion molecule primarily expressed in the intestinal tract. Ther
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
2. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
5. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
8. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
9. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/24/2013)... May 24 (HealthDay News) -- Patients hospitalized for heart ... they,re admitted on Mondays or in the morning, a ... stay are highest among heart failure patients admitted in ... who are scheduled to present their findings Saturday in ... Association of the European Society of Cardiology. ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... used to treat glaucoma may cause droopy eyelids and ... to a new study. The drugs, known as ... pressure, have already been shown to cause blurred vision, ... suggesting that the new findings could lead to labeling ... when prescribing these drugs, the researchers added, particularly as ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV ... consumers compare the features and services offered by ... released the rankings of the best rural ... viewing on their website. , BestSatelliteProviders.com ... Adam Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers ...
Breaking Medicine News(10 mins):Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... ,A new study shows that poor lung function during ... including birth weight, height, and gender. Researchers from Newcastle University ... all aged 14 years. Follow-up data also were obtained for ... showed that several factors were related to poorer lung function ...
... Energy and Commerce as part of an investigation into preventable ... report recommending further restrictions regarding duty hours for resident physicians ... safety, according to an article published in the January issue ... (JACR). In 2003, the Accreditation Council for ...
... 2010 Knee osteoarthritis (OA) accounts for more disability in ... proven cardiovascular and other health benefits, can increase stresses on ... the December 2009 issue of PM&R: The journal of ... knee, hip and ankle joint motions of running barefoot versus ...
... Extremity War Injuries Symposium was held in Washington, D.C., ... surgeons, researchers, experts from governmental agencies, and others to ... Iraq and Afghanistan and to discuss ways to synergize ... summarizing the findings from the symposium is published in ...
... pinpointed the prime factors identifying which elderly persons are ... The researchers, led by Jeffrey M. Lyness, M.D., professor ... in an article in the December issue of The ... for people in the high-risk group hold promise for ...
... , SCOTTSDALE, Ariz., Dec. 31 ... real estate investment trust, announced the completed acquisition of ... Angelo, Texas, Corsicana, Texas, and Fort Wayne, Indiana for ... is 100% leased to community hospitals that are wholly-owned ...
Cached Medicine News:Health News:News briefs from the January issue of Chest 2Health News:Institute of Medicine recommends stricter resident duty hour regulations to prevent medical errors 2Health News:Running shoes may cause damage to knees, hips and ankles 2Health News:Extremity war injuries: More research is needed 2Health News:Extremity war injuries: More research is needed 3Health News:Study identifies those elderly most at risk for major depression 2Health News:Healthcare Trust of America, Inc. Acquires a 92,500 SF Medical Office Portfolio Located in Texas and Indiana 2Health News:Healthcare Trust of America, Inc. Acquires a 92,500 SF Medical Office Portfolio Located in Texas and Indiana 3
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... The AMS 700 Series is an advanced three-part ... the abdomen, a pump placed in the scrotum ... corpora cavernosa. It closely simulates the look and ... for innovative penile implant technology, the AMS 700 ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
Medicine Products: